Koga T, Yano T, Ichikawa Y, Oizumi K, Mochizuki M
First Department of Internal Medicine, School of Medicine, Kurume University, Japan.
Chest. 1993 Jul;104(1):309-11. doi: 10.1378/chest.104.1.309.
Behçet's disease (BD) affects the lung as well as the intestine, central nervous system, kidney, and other organs. Pulmonary vasculitis is one of the most severe complications in BD because it can cause fatal bleeding. Corticosteroids and other immunosuppressive drugs have been used to treat pulmonary vasculitis, but the efficacy of these agents has not yet been established. We administered FK506, a novel immunosuppressive agent, as a treatment for BD. A 21-year-old woman presented definitive symptoms of BD, ie, repeated oral and genital ulcers, folliculitis, and panuveitis. The patient showed localized pulmonary infiltrates on her chest x-ray film that were histologically proved to be venulitis consistent with BD. These pulmonary infiltrates evanesced after the oral administration of FK506 for 8 weeks; in addition, the skin lesions and uveitis improved. This clinical observation indicates that FK506 is an effective agent in the treatment of pulmonary vasculitis associated with BD.
白塞病(BD)会累及肺部以及肠道、中枢神经系统、肾脏和其他器官。肺血管炎是BD最严重的并发症之一,因为它可导致致命性出血。皮质类固醇和其他免疫抑制药物已被用于治疗肺血管炎,但这些药物的疗效尚未得到证实。我们使用新型免疫抑制剂FK506来治疗BD。一名21岁女性出现了明确的BD症状,即反复出现口腔溃疡和生殖器溃疡、毛囊炎和全葡萄膜炎。患者胸部X线片显示局部肺部浸润,组织学检查证实为与BD相符的静脉炎。口服FK506 8周后,这些肺部浸润消失;此外,皮肤病变和葡萄膜炎也有所改善。这一临床观察表明,FK506是治疗与BD相关的肺血管炎的有效药物。